Business Wire

Business Wire, a wholly owned subsidiary of Berkshire Hathaway, is the global market leader in commercial news distribution.

Recent Articles By The Author

Accenture And Brandtone Collaborate To Deliver Next Generation Trade Promotion Services To Consumer Packaged Goods Companies In Asia Pacific

Accenture And Brandtone Collaborate To Deliver Next Generation Trade Promotion Services To Consumer Packaged Goods Companies In Asia Pacific

Accenture (NYSE:ACN) and Brandtone today announced a next generation trade promotion solution to help consumer packaged goods (CPG) companies have access to enhanced visibility, management and control of their promotional...

Chemtura To Be Acquired By LANXESS In ~$2.5 Billion All-Cash Transaction

Chemtura To Be Acquired By LANXESS In ~$2.5 Billion All-Cash Transaction

Chemtura Corporation (NYSE:CHMT) (Euronext Paris: CHMT) ("Chemtura") today announced that it has entered into a definitive agreement pursuant to which LANXESS AG ("LANXESS"), a global specialty chemicals company, will...

Statement From Albany International Corp. On The Death Of Company Chairman Emeritus J. Spencer Standish

Statement From Albany International Corp. On The Death Of Company Chairman Emeritus J. Spencer Standish

Albany International Corp. (NYSE:AIN) Chairman Emeritus J.

Masimo Foundation Co-Founds United For Oxygen Alliance

Masimo Foundation Co-Founds United For Oxygen Alliance

Masimo (NASDAQ: MASI) announced today that the Masimo Foundation has co-founded the United for Oxygen Alliance, as part of a Clinton Global Initiative (CGI) commitment.

Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1

Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today initial data from its ongoing Phase 1/2 study with ALN-GO1, an investigational RNAi therapeutic targeting glycolate...